ANDA 90541, held by Novast Labs. Ethinyl Estradiol; Norgestimate, Norgestimate; Ethinyl Estradiol.
As of Nov 16, 2026, ANDA 90541 (Tri-Lo-Linyah), held by Novast Labs, was first approved by FDA on Sep 2, 2022, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 2, 2022 | Original application | Approved | None posted |
| Tri-Lo-Linyah0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Tri-Lo-Linyah0.215MG; 0.025MG · tablet; oral | Norgestimate; Ethinyl Estradiol | None (tentative approval) |
| Tri-Lo-Linyah0.25MG; 0.025MG · tablet; oral | Norgestimate; Ethinyl Estradiol | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters